Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-I-SEP DMT Withdrawal in Inactive SPMS ≥50y
2024-516628-32-00Phase 3Authorised
- Sponsor
- CHU Rennes
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of interferon beta-1b, azathioprine, teriflunomide, glatiramer acetate, cyclophosphamide and 7 more in secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by CHU Rennes. Primary endpoint: Disability progression at 2 years. Planned start Oct 2024; status: authorised.
02
Drugs
interferon beta-1bazathioprineteriflunomideglatiramer acetatecyclophosphamide
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-516628-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516628-32-00.